NICE final guidance backs Angelini's Ontozry for focal-onset seizures

16 December 2021

The UK’s National Institute of Heath and Care Excellence (NICE) has published its final technology appraisal guidance (TAG) for Ontozry (cenobamate), a treatment for focal onset seizures in uncontrolled epilepsy from Arvelle Therapeutics, a unit of privately-held Italian drugmaker Angelini Pharma.

Cenobamate is recommended as an option for treating focal onset seizures with or without secondary generalized seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least two antiseizure medicines. It is recommended only if it is used as an add-on treatment, after at least one other add-on treatment has not controlled seizures, and treatment is started in a tertiary epilepsy service.

Epilepsy is a serious condition that affects one in 100 people in the UK and only 52% of those with condition are seizure free. People with uncontrolled seizures are more likely to experience co-morbidities, social stigmatization and poor quality of life.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK